Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)

BACKGROUND: Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated. This study aimed to compare S-1 and oxaliplatin (SOX) + bevacizumab (B-mab) with SOX + cetuximab (C-mab) in patients with pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishizawa, Yujiro, Haraguchi, Naotsugu, Kim, Hirotoshi, Ide, Yoshihito, Nakata, Ken, Okamura, Shu, Kudo, Toshihiro, Satoh, Taroh, Uemura, Mamoru, Matsuda, Chu, Mizushima, Tsunekazu, Murata, Kohei, Doki, Yuichiro, Eguchi, Hidetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381542/
https://www.ncbi.nlm.nih.gov/pubmed/34425776
http://dx.doi.org/10.1186/s12885-021-08690-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381542/
https://www.ncbi.nlm.nih.gov/pubmed/34425776
http://dx.doi.org/10.1186/s12885-021-08690-y

Ejemplares similares